Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125291805 | 12529180 | 5 | F | 20160615 | 20160826 | 20160705 | 20160901 | EXP | JP-ASTRAZENECA-2016SE71773 | ASTRAZENECA | 15862.00 | DY | F | Y | 62.00000 | KG | 20160901 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125291805 | 12529180 | 1 | PS | FORXIGA | DAPAGLIFLOZIN | 1 | Oral | 20 | MG | Y | 202293 | 5 | MG | TABLET | QOD | ||||
| 125291805 | 12529180 | 2 | SS | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | 0 | 2.5 | MG | TABLET | QD | |||||||
| 125291805 | 12529180 | 3 | C | VICTOZA | LIRAGLUTIDE | 1 | Subcutaneous | 0 | .9 | MG | INJECTION | QD | |||||||
| 125291805 | 12529180 | 4 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | Oral | 0 | 5 | MG | TABLET | QD | |||||||
| 125291805 | 12529180 | 5 | C | NU-LOTAN | LOSARTAN POTASSIUM | 1 | Oral | 0 | 50 | MG | TABLET | QD | |||||||
| 125291805 | 12529180 | 6 | C | FEXOFENADINE HYDROCHLORIDE. | FEXOFENADINE HYDROCHLORIDE | 1 | Oral | 0 | 60 | MG | TABLET | BID | |||||||
| 125291805 | 12529180 | 7 | C | MAGMITT | MAGNESIUM OXIDE | 1 | Oral | 0 | 330 | MG | TABLET | TID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125291805 | 12529180 | 1 | Type 2 diabetes mellitus |
| 125291805 | 12529180 | 2 | Hypercholesterolaemia |
| 125291805 | 12529180 | 3 | Type 2 diabetes mellitus |
| 125291805 | 12529180 | 4 | Hypertension |
| 125291805 | 12529180 | 5 | Hypertension |
| 125291805 | 12529180 | 6 | Urticaria |
| 125291805 | 12529180 | 7 | Constipation |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125291805 | 12529180 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125291805 | 12529180 | Haemoconcentration | |
| 125291805 | 12529180 | Off label use | |
| 125291805 | 12529180 | Product use issue | |
| 125291805 | 12529180 | Renal infarct |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125291805 | 12529180 | 1 | 20160615 | 20160623 | 0 | |
| 125291805 | 12529180 | 3 | 20140509 | 0 | ||
| 125291805 | 12529180 | 5 | 201006 | 0 | ||
| 125291805 | 12529180 | 7 | 201205 | 0 |